In particular, the level of tumor‐infiltrating CD8+ T lymphocytes is often a predictor of patient survival and response to immunotherapy,24, 25, 26, 27, 28, 29, 30, 31 and both anti‐CTLA‐4 and anti‐PD‐1 treatments can induce CD8+ T‐cell expansion. The gene discussed is CD8A; the disease is neoplasm.